newsfilter
← Latest News
ACCESS Newswire·

FSD Pharma Selected to Present its Phase 1 Data on Lucid-MS at MSMilan 2023 – 9th Joint ECTRIMS-ACTRIMS Meeting for October 11-13, 2023

Targeting the Approximate $22 Billion Multiple Sclerosis Drug Treatment MarketTORONTO, ON / ACCESSWIRE / August 15, 2023 / FSD Pharma Inc. ("FSD Pharma" or the